A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia

2017 ◽  
Vol 54 (1) ◽  
pp. 104 ◽  
Author(s):  
CH Liu ◽  
XF Zhang ◽  
LV De-Sheng ◽  
M Li ◽  
GE Sun
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Meta Analysis ◽  
Growth Factor Receptor ◽  
Safety And Efficacy ◽  
Epidermal Growth

scholarly journals Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance

Oncotarget ◽  
2018 ◽  
Vol 9 (20) ◽  
pp. 15418-15434 ◽  
Author(s):  
Carina Heydt ◽  
Sebastian Michels ◽  
Kenneth S. Thress ◽  
Sven Bergner ◽  
Jürgen Wolf ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Epidermal Growth ◽  
Novel Approaches ◽  
Inhibitor Resistance

scholarly journals Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma

RSC Advances ◽  
2018 ◽  
Vol 8 (70) ◽  
pp. 40387-40394 ◽  
Author(s):  
Mohamed W. Attwa ◽  
Adnan A. Kadi ◽  
Hany W. Darwish ◽  
Ali S. Abdelhameed
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Third Generation ◽  
Epidermal Growth ◽  
Egfr Tki

Olmutinib (OTB, Olita™) is an orally available third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

Sign in / Sign up

Export Citation Format

Share Document